Walleye Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Walleye Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-89,200	Closed	-$3.94M	–	5024
2025 Q1	$3.94M	Buy	89,200 +88,000	+7,333%	+$4.05M	0.02%	947
2024 Q4	$43.4K	Buy	+1,200	New	+$41.9K	﹤0.01%	4387
2024 Q3	–	Sell	-12,900	Closed	-$486K	–	5846
2024 Q2	$486K	Buy	12,900 +6,700	+108%	+$282K	﹤0.01%	3540
2024 Q1	$305K	Buy	+6,200	New	+$287K	﹤0.01%	3653

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Capital's SWTX Position: Q3 2025 in Review

Walleye Capital sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 5,882 shares — an estimated $276K sold.

Walleye Capital first reported a position in SWTX in Q2 2022 and held it in 9 quarters. The position peaked at $9.17M in Q3 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Walleye Capital reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 5,882 SpringWorks Therapeutics shares in Q3 2025, an estimated $276K.
Walleye Capital first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 9 quarters.
Walleye Capital's SpringWorks Therapeutics position peaked at $9.17M in Q3 2024.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.